RT Book, Section A1 Dieter, Robert S. A1 Clavijo, Leonardo A1 Stevens, Scott L. A1 Laird, John R. A2 Dieter, Robert S. A2 Dieter, Raymond A. A2 Dieter, Raymond A. SR Print(0) ID 1127169011 T1 The Vascular Biology and Clinical Efficacy of Drug-Eluting Stents for the Treatment of Peripheral Arterial Disease T2 Peripheral Arterial Disease YR 2009 FD 2009 PB McGraw-Hill Education PP New York, NY SN 9780071481793 LK accesscardiology.mhmedical.com/content.aspx?aid=1127169011 RD 2024/03/28 AB Nearly 10% of the population older than 65 years has atherosclerotic lower extremity peripheral arterial disease. Older patients and those with risk factors may have up to a 25% incidence of lower extremity peripheral arterial disease.1 Percutaneous vascular interventions are rapidly emerging as a less invasive therapy for symptomatic lower extremity occlusive arterial disease.2,3,4 Despite recent advances, restenosis remains a significant problem with catheter-based revascularization. By delivering high local doses, drug-eluting stents have the potential to overcome the limitations of restenosis and advance stent-based therapies for lower extremity peripheral arterial disease (Table 39-1).